Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo

International Journal of Oncology

Volumn 36, Issue 4, 2010, Pages 823-831

  Takenaka, Satoshi ^a,b   Naka, Norifumi ^a   Araki, Nobuhito ^a   Hashimoto, Nobuyuki ^b   Ueda, Takafumi ^c   Yoshioka, Kiyoko ^a   Yoshikawa, Hideki ^b   Itoh, Kazuyuki ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Morphology; SS18 SSX; Synovial sarcoma

Indexed keywords

HYBRID PROTEIN; MYOSIN LIGHT CHAIN KINASE; NANOPARTICLE; SMALL INTERFERING RNA; SS18 SSX PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FOCAL ADHESION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUDE MOUSE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RNA INTERFERENCE; RNA ISOLATION; SYNOVIAL SARCOMA; TUMOR GROWTH; TUMOR XENOGRAFT;

ADULT; ANIMALS; CALCIUM-BINDING PROTEINS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; DOWN-REGULATION; FOCAL ADHESIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; MALE; MICE; MICE, NUDE; MYOSIN-LIGHT-CHAIN KINASE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; RNA INTERFERENCE; SARCOMA, SYNOVIAL; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77749261678     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000559     Document Type: Article

References (41)

1. Smith S, Reeves BR, Wong L and Fisher C: A consistent chromosome translocation in synovial sarcoma. Cancer Genet Cytogenet 26: 179-180, 1987.
2. Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, Gusterson BA and Cooper CS: Identification of novel genes, SYT and SSX, involved in the t(X;18) (p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 7: 502-508, 1994.
3. Crew AJ, Clark J, Fisher C, Gill S, Grimer R, Chand A, Shipley J, Gusterson BA and Cooper CS: Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J 14: 2333-2340, 1995.
4. Skytting B, Nilsson G, Brodin B, Xie Y, Lundeberg J, Uhlen M and Larsson O: A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst 91: 974-975, 1999.
5. Takenaka S, Ueda T, Naka N, Araki N, Hashimoto N, Myoui A, Ozaki T, Nakayama T, Toguchida J, Tanaka K, Iwamoto Y, Matsumine A, Uchida A, Ieguchi M, Kaya M, Wada T, Baba I, Kudawara I, Aoki Y and Yoshikawa H: Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep 19: 467-476, 2008.
6. Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J and Aulitzky WE: Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 102: 2236-2239, 2003.
7. Koldehoff M, Steckel NK, Beelen DW and Elmaagacli AH: Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 7: 47-55, 2007.
8. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A and Dejean A: Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76: 345-356, 1994.
9. De Bruijn DR, Baats E, Zechner U, de Leeuw B, Balemans M, Olde Weghuis D, Hirning-Folz U and Geurts van Kessel AG: Isolation and characterization of the mouse homolog of SYT, a gene implicated in the development of human synovial sarcomas. Oncogene 13: 643-648, 1996.
10. De Bruijn DR, Peters WJ, Chuva de Sousa Lopes SM, van Dijk AH, Willemse MP, Pfundt R, de Boer P and Geurts van Kessel A: Targeted disruption of the synovial sarcoma-associated SS18 gene causes early embryonic lethality and affects PPARBP expression. Hum Mol Genet 15: 2936-2944, 2006.
11. Perani M, Ingram CJ, Cooper CS, Garrett MD and Goodwin GH: Conserved SNH domain of the proto-oncoprotein SYT interacts with components of the human chromatin remodelling complexes, while the QPGY repeat domain forms homo-oligomers. Oncogene 22: 8156-8167, 2003.
12. Thaete C, Brett D, Monaghan P, Whitehouse S, Rennie G, Rayner E, Cooper CS and Goodwin G: Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum Mol Genet 8: 585-591, 1999.
13. Soulez M, Saurin AJ, Freemont PS and Knight JC: SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX colocalize with the human Polycomb group complex. Oncogene 18: 2739-2746, 1999.
14. Margolin JF, Friedman JR, Meyer WK, Vissing H, Thiesen HJ and Rauscher FJ III: Kruppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci USA 91: 4509-4513, 1994.
15. Moosmann P, Georgiev O, Le Douarin B, Bourquin JP and Schaffner W: Transcriptional repression by RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1. Nucleic Acids Res 24: 4859-4867, 1996.
16. Gure AO, Tureci O, Sahin U, Tsang S, Scanlan MJ, Jager E, Knuth A, Pfreundschuh M, Old LJ and Chen YT: SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer 72: 965-971, 1997.
17. Naka N, Joyama S, Tsukamoto Y, Yoshioka K, Hashimoto N, Ujiiye T, Hayashi T, Kawase M, Mano M, Ishiguro S, Myoui A, Ueda T, Yoshikawa H, Araki N and Itoh K: Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification. J Mol Diagn 7: 187-197, 2005.
18. + T cells. Clin Cancer Res 12: 398-404, 2006.
19. + T cell responses to SSX-4 in melanoma patients. J Immunol 174: 5092-5099, 2005.
20. Ayyoub M, Brehm M, Metthez G, Talbot S, Dutoit V, Taub RN, Keohan ML, Gure AO, Chen YT, Williamson B, Jungbluth AA, Old LJ, Hesdorffer CS and Valmori D: SSX antigens as tumor vaccine targets in human sarcoma. Cancer Immun 3: 13, 2003.
21. Nagai M, Tanaka S, Tsuda M, Endo S, Kato H, Sonobe H, Minami A, Hiraga H, Nishihara H, Sawa H and Nagashima K: Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci USA 98: 3843-3848, 2001.
22. Dos Santos NR, de Bruijn DR, Kater-Baats E, Otte AP and van Kessel AG: Delineation of the protein domains responsible for SYT, SSX, and SYT-SSX nuclear localization. Exp Cell Res 256: 192-202, 2000.
23. Haldar M, Hedberg ML, Hockin MF and Capecchi MR: A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. Cancer Res 69: 3657-3664, 2009.
24. Haldar M, Hancock JD, Coffin CM, Lessnick SL and Capecchi MR: A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 11: 375-388, 2007.
25. Eid JE, Kung AL, Scully R and Livingston DM: p300 interacts with the nuclear proto-oncoprotein SYT as part of the active control of cell adhesion. Cell 102: 839-848, 2000.
26. Yagi N, Manabe I, Tottori T, Ishihara A, Ogata F, Kim JH, Nishimura S, Fujiu K, Oishi Y, Itaka K, Kato Y, Yamauchi M and Nagai R: A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res 69: 6531-6538, 2009.
27. Yamauchi M, Kusano H, Saito E, Iwata T, Nakakura M, Kato Y, Uochi T, Akinaga S and Aoki N: Improved formulations of antisense oligodeoxynucleotides using wrapped liposomes. J Control Release 114: 268-275, 2006.
28. Xie Y, Skytting B, Nilsson G, Gasbarri A, Haslam K, Bartolazzi A, Brodin B, Mandahl N and Larsson O: SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18) (p11.2;q11.2) translocation. Cancer Res 62: 3861-3867, 2002.
29. Tsuda M, Watanabe T, Seki T, Kimura T, Sawa H, Minami A, Akagi T, Isobe K, Nagashima K and Tanaka S: Induction of p21(WAF1/CIP1) by human synovial sarcoma-associated chimeric oncoprotein SYT-SSX1. Oncogene 24: 7984-7990, 2005.
30. Fernebro J, Francis P, Eden P, Borg A, Panagopoulos I, Mertens F, Vallon-Christersson J, Akerman M, Rydholm A, Bauer HC, Mandahl N and Nilbert M: Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. Int J Cancer 118: 1165-1172, 2006.
31. Saito T, Nagai M and Ladanyi M: SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Res 66: 6919-6927, 2006.
32. Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, Downs-Kelly E, Corless CL, Rubin BP, van de Rijn M, Ladanyi M and Nielsen TO: TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 31: 240-246, 2007.
33. Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de Rijn M, Poulin N, van Kessel AG and Nielsen TO: Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 68: 4303-4310, 2008.
34. Barco R, Hunt LB, Frump AL, Garcia CB, Benesh A, Caldwell RL and Eid JE: The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway. Mol Biol Cell 18: 4003-4012, 2007.
35. Ishida M, Miyamoto M, Naitoh S, Tatsuda D, Hasegawa T, Nemoto T, Yokozeki H, Nishioka K, Matsukage A, Ohki M and Ohta T: The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(X;18) synovial sarcoma. Mol Cell Biol 27: 1348-1355, 2007.
36. Chittezhath M, Frump AL, Jourquin J, Lobdell N and Eid JE: The proto-oncoprotein SYT (SS18) controls ATP release and regulates cyst formation by polarized MDCK cells. Exp Cell Res 314: 3551-3562, 2008.
37. Kim J, Swee M and Parks WC: Cytosolic SYT/SS18 isoforms are actin-associated proteins that function in matrix-specific adhesion. PLoS One 4: E6455, 2009.
38. Freedman VH and Shin SI: Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3: 355-359, 1974.
39. Sanders LC, Matsumura F, Bokoch GM and de Lanerolle P: Inhibition of myosin light chain kinase by p21-activated kinase. Science 283: 2083-2085, 1999.
40. Tang Y, Chen Z, Ambrose D, Liu J, Gibbs JB, Chernoff J and Field J: Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol 17: 4454-4464, 1997.
41. Callow MG, Clairvoyant F, Zhu S, Schryver B, Whyte DB, Bischoff JR, Jallal B and Smeal T: Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem 277: 550-558, 2002.